Candriam Equities L Oncology Fund Class N EUR CapRegistrati per vedere i rating |
Storico dei rendimenti | 31/03/2025 |
Crescita di 1000 (EUR) | Grafico Interattivo |
Sintesi | ||
NAV 03/04/2025 | EUR 134,180 | |
Var.Ultima Quotazione | -3,31% | |
Categoria Morningstar™ | Azionari Settore Salute | |
Categoria Assogestioni | Azionari salute | |
Isin | LU2346866317 | |
Fund Size (Mil) 03/04/2025 | USD 1531,33 | |
Share Class Size (Mil) 03/04/2025 | EUR 5,19 | |
Entrata (max) | - | |
Spese correnti 28/02/2025 | 2,35% |
Obiettivo d'Investimento Dichiarato: Candriam Equities L Oncology Fund Class N EUR Cap |
The objective of the sub-fund is to use discretionary management to benefit from the performance of the market in global equities of companies in the field of oncology (cancer research, diagnosis, treatment, etc.) in order to respond to one of the serious long-term challenges of sustainable development. The sub-fund therefore seeks to produce a return for investors while generating a positive social impact over the long term, by selecting companies that address certain societal challenges and mobilise resources in the fight against cancer. |
Rendimenti % (EUR) | |||||||||||||
|
Gestione | ||
Nome del Gestore Inizio Gestione | ||
Linden Thomson 29/02/2024 | ||
Servaas Michielssens 01/08/2024 | ||
Data di Partenza 26/01/2023 |
Pubblicità |
Indice | |
Benchmark Dichiarato | Indice di Categoria Morningstar |
MSCI World NR USD | Morningstar Gbl Health TME NR USD |
Target Market | ||||||||||||||||||||
|
Composizione del Fondo Candriam Equities L Oncology Fund Class N EUR Cap | 28/02/2025 |
|
|
Primi 5 Titoli | Settore | % |
![]() | ![]() | 7,34 |
![]() | ![]() | 5,01 |
![]() | ![]() | 4,38 |
![]() | ![]() | 4,31 |
![]() | ![]() | 4,29 |
![]() | ||
![]() ![]() ![]() | ||
Candriam Equities L Oncology Fund Class N EUR Cap |